With an increase of over 57% since the start of 2023, Virbac is currently the best performer in the SBF120 index (excluding CAC40 stocks), boosted at the end of the year by a cumulative jump of 16.4% on December 19 and 20.

For the record, the stock was boosted by an increase in its targets for 2023, with organic sales growth expected to be around 4% and an adjusted EBIT margin of around 15% at constant exchange rates.

With regard to 2024, the veterinary drugs manufacturer said it was currently forecasting organic sales growth of between 4% and 6%, and an adjusted EBIT margin of around 15% at constant exchange rates.

The 2024 guidance leaves room for improvement, during 2024, including with the non-recurrence of the impact of the 2023 cyber-attack", estimated Oddo BHF, maintaining its "outperform" opinion with a price target raised from 290 to 385 euros.

Copyright (c) 2023 CercleFinance.com. All rights reserved.